Revvity (RVTY) continues to maintain its status in the market, despite speculations of an earnings decline in its Q1 reports. This impression is bolstered by a steady dividend program of $0.07 per share due in August. Multiple adjustments were made to Revvity's price target ahead of its Q1 earnings, with BofA and Baird making notable cuts. However, Revvity surpassed estimates for its Q4 earnings. The company recently got FDA's approval for a TB test system that significantly reduces testing time, contributing to their Q4 revenue growth. While there have been lobbying disclosures and initial concerns about policy challenges and funding, Revvity's market performance remains resilient. A significant move came from one of Revvity's directors who made a publicized stock sale. Revvity's financial results for 2024 were in line with expectations, despite suggestions of lower earnings for 2025. Lastly, Revvity's RVTY stock has seen a decent return of 30% over the past five years, despite some stock price lowering and analyst downgrades.
Revvity RVTY News Analytics from Tue, 09 May 2023 07:00:00 GMT to Sat, 26 Apr 2025 20:11:50 GMT -
Rating 4
- Innovation 5
- Information -1
- Rumor 1
